Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “placebo” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 588
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 588 pipeline programs matching "placebo" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

588 results for “placebo” Back to intelligence hub

Search results

Page 19 of 25
  1. Ramelteon or Placebo

    Takeda

    Sleep Apnea, Obstructive

    phase 2 small molecule completed

    1 trial
  2. Reparixin, Placebo - Tablet for oral use

    Dompe' Farmaceutici S.p.A.

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial
  3. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial
  4. SAGE-718-matching placebo

    SUPERNUS PHARMACEUTICALS, INC.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial
  5. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial
  6. SAR443765 / LUNSEKIMIG, Matched Placebo to Test

    Sanofi-aventis Healthcare Pty Ltd

    Dermatitis atopic

    phase 2 small molecule active

    1 trial
  7. SAR444656, Matched Placebo

    Sanofi-aventis Healthcare Pty Ltd

    hidradenitis suppurativa

    phase 2 small molecule active

    1 trial
  8. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial
  9. Sibeprenlimab, Sibeprenlimab placebo

    Otsuka Beijing Research Institute

    Treatment of Sjögren’s disease

    phase 2 small molecule active

    1 trial
  10. TAK-954 Placebo

    Takeda

    Postoperative Gastrointestinal Dysfunction

    phase 2 small molecule completed

    1 trial
  11. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial
  12. Tarperprumig Placebo, Tarperprumig

    Alexion Europe SAS

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

    phase 2 small molecule active

    1 trial
  13. The Placebo composition is the same of the IMP except the active ingredient

    Fondazione Telethon ETS

    Optic Pathway Glioma (OPG)

    phase 2 small molecule active

    1 trial
  14. Tildacerfont/Placebo

    SPRUCE BIOSCIENCES, INC.

    Congenital Adrenal Hyperplasia

    phase 2 small molecule terminated

    2 trials
  15. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial
  16. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial
  17. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial
  18. VCH-222 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 2 small molecule completed

    1 trial
  19. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial
  20. Vialed Saline Placebo, ALXN2030

    Alexion Europe SAS

    Antibody-Mediated Rejection after Kidney Transplantation

    phase 2 small molecule active

    1 trial
  21. WJMSCs Vs. placebo

    The First People's Hospital of Lianyungang

    Ischemic Cardiomyopathy

    phase 2 mab active

    1 trial
  22. XB2001 or Placebo

    XBiotech Germany GmbH

    Pancreatic Cancer

    phase 2 mab active

    1 trial
  23. ZASOCITINIB, Matching Placebo for TAK-279

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial
  24. aleniglipron or placebo

    Structure Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.